CV Therapeutics completes Regadenoson trial enrollment

By Elaine Rigoli

Tampa, Fla., June 7 - CV Therapeutics, Inc. said it has completed patient enrollment of the second phase 3 Regadenoson trial, with data now anticipated in the second half of 2006.

In this trial, patients 18 years or older with the clinical need for a pharmacologic stress myocardial perfusion imaging (MPI) study were eligible to participate, according to a news release.

Individuals who had an acute myocardial infarction or unstable angina within three months, or coronary revascularization within six months, were not permitted to participate in the study.

All study participants received a clinically indicated baseline MPI study using Adenoscan (adenosine injection).

Participants then were randomized in a double-blinded fashion to receive either Regadenoson or Adenoscan in a second MPI study.

Each patient's scan is classified as indicating normal, moderate or severe ischemia. Baseline and blinded scans then are evaluated to determine whether the scans are comparable.

CV Therapeutics, based in Palo Alto, Calif., is a biopharmaceutical company focused on applying molecular cardiology to the development of novel, small-molecule drugs for the treatment of cardiovascular diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.